11,365 Shares in Cardinal Health, Inc. $CAH Purchased by Callan Family Office LLC

Callan Family Office LLC purchased a new stake in shares of Cardinal Health, Inc. (NYSE:CAH - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 11,365 shares of the company's stock, valued at approximately $2,700,000.

A number of other large investors have also added to or reduced their stakes in the stock. Gambit Capital Management LLC purchased a new position in Cardinal Health in the second quarter valued at about $229,000. Laidlaw Wealth Management LLC bought a new position in shares of Cardinal Health during the 2nd quarter valued at approximately $609,000. C M Bidwell & Associates Ltd. purchased a new stake in shares of Cardinal Health during the 2nd quarter worth approximately $683,000. Keebeck Wealth Management bought a new stake in shares of Cardinal Health in the 2nd quarter worth approximately $348,000. Finally, Keating Financial Advisory Services Inc. bought a new stake in shares of Cardinal Health in the 2nd quarter worth approximately $56,000. Hedge funds and other institutional investors own 87.17% of the company's stock.

Trending Headlines about Cardinal Health

Here are the key news stories impacting Cardinal Health this week:

• Positive Sentiment: Royal Bank of Canada initiated coverage with an “outperform” rating and a $276 price target, implying meaningful upside from recent trading levels. RBC cited Cardinal Health’s higher-margin services as a potential earnings-growth driver. RBC initiates coverage of Cardinal Health
• Positive Sentiment: Wall Street remains broadly constructive, with 16 analysts rating CAH a Buy and three assigning a Hold rating. The consensus rating is “Moderate Buy,” with an average price target of approximately $266.56. Zacks also identified Cardinal Health as a potentially attractive long-term value stock. Zacks value-stock analysis
• Positive Sentiment: Cardinal Health’s latest quarter delivered adjusted earnings per share of $2.91, well above the $2.42 consensus estimate, while revenue increased 5.8% year over year. Fiscal 2027 EPS guidance of $12.40–$12.60 supports the longer-term earnings case.
• Neutral Sentiment: The company declared a quarterly dividend of $0.5158 per share, equivalent to $2.06 annually and a yield of about 0.9%. The payout offers modest income support but is unlikely to be a major near-term catalyst.
• Negative Sentiment: Several executives sold sizable holdings around $235–$237 per share. CEO Jason Hollar sold 124,529 shares worth about $29.4 million, while other executive and insider sales—including those by Deborah Weitzman, Stephen Mason, Michelle Greene, Jessica Mayer and Mary Scherer—totaled roughly $20 million more. The concentrated selling and substantial reductions in insider ownership may encourage profit-taking concerns after CAH’s strong advance. Cardinal Health insider sales
• Negative Sentiment: Investors may also question the durability of the latest earnings beat because part of the improvement reportedly reflected a one-time tariff refund, potentially limiting the stock’s upside if recurring earnings growth does not match expectations. Cardinal Health earnings analysis

Cardinal Health Trading Up 0.4%

Shares of CAH stock opened at $229.48 on Friday. The firm's 50 day moving average is $232.02 and its 200 day moving average is $217.86. The stock has a market capitalization of $53.37 billion, a P/E ratio of 31.74, a PEG ratio of 1.23 and a beta of 0.49. Cardinal Health, Inc. has a 12 month low of $145.87 and a 12 month high of $258.30.

Cardinal Health (NYSE:CAH - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported $2.91 earnings per share for the quarter, beating analysts' consensus estimates of $2.42 by $0.49. Cardinal Health had a net margin of 0.67% and a negative return on equity of 98.53%. The business had revenue of $63.67 billion during the quarter, compared to analyst estimates of $65.15 billion. During the same period in the previous year, the business earned $2.08 EPS. Cardinal Health's revenue was up 5.8% compared to the same quarter last year. Cardinal Health has set its FY 2027 guidance at 12.400-12.600 EPS. On average, equities analysts predict that Cardinal Health, Inc. will post 12.54 EPS for the current year.

Cardinal Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be given a $0.5158 dividend. The ex-dividend date is Thursday, October 1st. This represents a $2.06 annualized dividend and a dividend yield of 0.9%. Cardinal Health's payout ratio is 28.49%.

Insider Buying and Selling

In related news, CEO Jason M. Hollar sold 80,000 shares of the business's stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $235.74, for a total transaction of $18,859,200.00. Following the sale, the chief executive officer directly owned 235,132 shares in the company, valued at approximately $55,430,017.68. The trade was a 25.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Stephen M. Mason sold 35,000 shares of the stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $236.40, for a total value of $8,274,000.00. Following the sale, the chief executive officer directly owned 18,061 shares in the company, valued at $4,269,620.40. This trade represents a 65.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 210,271 shares of company stock valued at $49,626,657 in the last 90 days. Corporate insiders own 0.12% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on CAH. Morgan Stanley increased their price objective on Cardinal Health from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Wednesday, August 12th. Bank of America boosted their target price on Cardinal Health from $240.00 to $260.00 and gave the company a "buy" rating in a research note on Thursday, July 2nd. Barclays upped their price target on Cardinal Health from $258.00 to $275.00 and gave the company an "overweight" rating in a research report on Thursday, August 13th. TD Cowen increased their price target on Cardinal Health from $275.00 to $280.00 and gave the stock a "buy" rating in a research note on Thursday, August 13th. Finally, Evercore reissued an "outperform" rating and issued a $270.00 price objective on shares of Cardinal Health in a report on Wednesday, August 12th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, Cardinal Health has an average rating of "Moderate Buy" and a consensus price target of $266.56.

Cardinal Health Profile

Cardinal Health is a multinational healthcare services and products company headquartered in Dublin, Ohio. Tracing its roots to the early 1970s, the company has grown into a major provider of supply chain and distribution services for the healthcare sector. Cardinal Health operates across a range of service lines that support hospitals, health systems, pharmacies, physician offices and clinical laboratories.

The company's core activities include the wholesale distribution of branded and generic pharmaceuticals, the supply and distribution of medical-surgical products, and the provision of logistics and inventory management solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source